South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age1-14
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

About this trial

In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%. A number of in vitro studies have shown that arsenic trioxide (ATO) can selectively inhibit the growth and induce apoptosis in a variety of leukemia cell lines, suggesting that ATO as a synergist combined with other common chemotherapy drugs may provide a new target for the treatment of relapsed ALL. Realgar Indigo naturalis formula is a compound traditional Chinese medicine preparation developed in China. The main component of realgar is arsenic tetrasulfide (As4S4), which can produce similar pharmacological effects to ATO. Based on the R3 protocol, this study plans to perform a double-blind randomized controlled trial, and to randomly combine compound Huangdai tablets with compound Huangdai tablets in the treatment of intermediate and high risk ALL children, in order to improve the MRD negative rate after induction therapy in this group of children, which may provide a new method for the clinical treatment of relapsed ALL.

Eligibility criteria

Qualifiers

B or T cell type;

the first recurrence;

the risk stratification was medium or high risk.

Disqualifiers

mature B cell leukemia;

acute mixed phenotype leukemia;

patients with positive BCR/ABL fusion gene;

the second tumor

Trial design

Treatments tested in this trial

  • Realgar Indigo naturalis formula
  • Conventional chemotherapy

Treatment groups

210 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Lead sponsor

First Affiliated Hospital, Sun Yat-Sen University

Collaborator

Third Affiliated Hospital, Sun Yat-Sen University

Collaborator

Zhujiang Hospital

Collaborator

The First Affiliated Hospital of Guangzhou Medical University

Collaborator

Guangzhou First People's Hospital

Collaborator

Huizhou Municipal Central Hospital

Collaborator

First Affiliated Hospital of Shantou University Medical College

Collaborator

Zhongshan People's Hospital, Guangdong, China

Collaborator

Zhongshan Bo Ai Hospital

Collaborator

First Affiliated Hospital of Guangxi Medical University

Collaborator

LiuZhou People's Hospital

Collaborator

Second Xiangya Hospital of Central South University

Collaborator

Hainan People's Hospital

Collaborator